Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods
View Patent ↗The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. The invention also provides, among other things, methods of inhibiting virus replication, methods of vaccination and methods of treating vaccinated subjects showing signs or otherwise at risk for of vaccination-induced disease.
1. A smallpox vaccine composition for vaccinating a subject against smallpox comprising:
i) recombinant vaccinia virus having integrated into its viral genome an exogenous sequence encoding a prodrug converting polypeptide under transcriptional control of a vaccinia virus regulatory region, wherein the sequence is integrated into a non-essential intergenic region of the vaccinia virus genome, wherein the prodrug converting polypeptide converts a prodrug into a drug that inhibits viral replication; and
ii) a pharmaceutically acceptable carrier, wherein the composition comprises the recombinant vaccinia virus in an amount sufficient to vaccinate the subject against smallpox.
2. A smallpox vaccine composition for vaccinating a subject against smallpox comprising:
i) recombinant vaccinia virus having integrated into its viral genome an exogenous sequence encoding a prodrug converting polypeptide under transcriptional control of a vaccinia virus regulatory region, wherein the sequence is integrated into a non-essential intergenic region of the vaccinia virus genome, wherein the prodrug converting polypeptide converts a prodrug into a drug that inhibits viral replication, wherein the vaccinia virus is a smallpox vaccine strain selected from the group of strains consisting of Lister/Elstree, New York City Board of Health, Temple of Heaven and LC16m0; and
ii) a pharmaceutically acceptable carrier, wherein the composition comprises the recombinant vaccinia virus in an amount sufficient to vaccinate the subject against smallpox.
3. The smallpox vaccine composition according to claim 2 , wherein the prodrug converting polypeptide is a thymidine kinase from herpes simplex virus or cytomegalovirus.
4. The smallpox vaccine composition according to claim 2 , wherein the prodrug converting polypeptide is a fusion protein.
5. The smallpox vaccine composition according to claim 4 , wherein the fusion protein is E. coli thymidine kinase/thymidylate kinase (tk/tmk).
6. The smallpox vaccine composition according to claim 2 , wherein the prodrug is a nucleoside analog.
7. The smallpox vaccine composition according to claim 2 , wherein the prodrug is selected from the group consisting of 3′ azido-2′,3′-dideoxythymidine (AZT), gancyclovir (GCV) and acyclovir (ACV).
8. The smallpox vaccine composition according to claim 2 , comprising ≧10 8 pfu/ml of vaccinia virus.
9. The smallpox vaccine composition according to claim 2 , wherein the vaccine is administered by scarification.
10. A recombinant vaccinia virus having integrated into its viral genome an exogenous sequence encoding a prodrug converting polypeptide under transcriptional control of a vaccinia virus regulatory region, wherein the sequence is integrated into a non-essential intergenic region of the vaccinia virus genome, wherein the prodrug converting polypeptide converts a prodrug into a drug that inhibits viral replication, and wherein the prodrug converting polypeptide is a fusion protein.
11. A recombinant vaccinia virus having integrated into its viral genome an exogenous sequence encoding a prodrug converting polypeptide under transcriptional control of a vaccinia virus regulatory region, wherein the sequence is integrated into a non-essential intergenic region of the vaccinia virus genome, wherein the prodrug converting polypeptide converts a prodrug into a drug that inhibits viral replication, wherein the prodrug converting polypeptide is a fusion protein, and wherein the vaccinia is a smallpox vaccine strain selected from the group of strains consisting of Lister/Elstree, New York City Board of Health, Temple of Heaven strain and LC16m0.
12. The virus according to claim 11 , wherein the fusion protein is E. coli thymidine kinase/thymidylate kinase (tk/tmk).
13. The virus according to claim 11 , wherein the prodrug is a nucleoside analog.
14. The virus according to claim 11 , wherein the vaccinia virus has a reversion rate of less than 1:10 4 in cell culture.